# 1 The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free

### 2 and basal/squamous muscle-invasive bladder cancer survival and better targeted

- 3 strategies for immune checkpoint blocking.
- 4 Simon C. Baker<sup>1,\*</sup>, Andrew S. Mason<sup>1</sup>, Raphael G. Slip<sup>1</sup>, Pontus Eriksson<sup>2</sup>, Gottfrid Sjödahl<sup>2</sup>,
- 5 Ludwik K Trejdosiewicz<sup>1</sup> and Jennifer Southgate<sup>1</sup>.
- 6
- 7 Affiliation
- <sup>8</sup> <sup>1</sup>Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical
- 9 Research Institute, University of York, Heslington, York YO10 5DD, UK.
- <sup>2</sup>Lund University Cancer Centre, Lunds Universitet, Box 117, 221 00 Lund, Sweden.

11

- 12 Contact Information for Corresponding Author\* (Address as above)
- 13 Tel: +44 1904 328706
- 14 E-mail address: simon.baker@york.ac.uk

15

16 Keywords: urothelium, IFNg, non muscle invasive bladder cancer, APOBEC

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 17 Abstract

Intravesical Bacillus Calmette-Guérin vaccine (BCG) is an established immunotherapeutic in bladder cancer (BlCa), provoking inflammation leading to tumour-specific immunity. Immune checkpoint blockers such as anti-PD-L1 have potential for enhancing tumour-specific lymphocyte-mediated cytotoxicity in BCG-refractive or advanced disease. In both cases, Interferon-gamma (IFNγ) plays a central role. We investigated the transcriptomic response of normal human urothelium to IFNγ to disentangle mechanisms of BCG and anti-PD-L1 therapy failure.

Exposure of differentiated human urothelium to IFNγ resulted in upregulated MHC class I and
class II and *de novo* expression of CXCL9-11 chemokine genes. Normal urothelium expressed
only immuno-inhibitory B7 family members: PD-L1 expression was induced by IFNγ, whereas
VISTA was expressed constitutively.

A urothelial IFNγ response gene set was derived and used for unsupervised clustering of
tumours, which predicted longer recurrence-free survival in non-muscle invasive bladder
cancer (NMIBC). In muscle invasive bladder cancer (MIBC), the IFNγ-signature split the
basal/squamous consensus subtype, with significantly worse overall survival when
weak/absent.

Normal urothelium has few resident lymphocytes. Tumour cell killing requires recruitment
 and activation of IFNγ-secreting pro-inflammatory/cytotoxic lymphocytes while surmounting
 both innate (VISTA) and upregulated (PD-L1) inhibitory mechanisms. This study offers
 supportive evidence for strategies to enhance immunotherapy *via* the IFNγ and VISTA/PD-L1
 nexus.

### 39 Patient Summary

Immunotherapy brings promise of harnessing a patient's own immune system to seek and destroy malignant cells, but it has yet to deliver widespread clinical benefit. We exposed human urothelium to interferon gamma, a key messenger of the immune system and identified a novel signature of 33 genes that predicted cancers with better outcomes. Our study revealed alternative strategies for targeting checkpoint proteins to improve immunotherapy in the future.

#### 46 Manuscript

BCG is widely used in NMIBC therapy as a potent inducer of inflammation, provoking
infiltration by IFNγ-secreting proinflammatory leukocytes which become exposed to tumour
neoantigens, resulting in tumour-specific immunity [1]. In an orthotopic MB49 mouse BICa
model, IFNγ was critical for intrinsic tumour surveillance and an *lfng*-knockout rendered BCG
ineffective [2].

52 We report the results of exposing mitotically-quiescent (G0-arrested), *in vitro*-differentiated 53 normal human urothelium from six independent donors to 200 U/mL IFN $\gamma$  to generate a 54 tissue-specific urothelial response transcriptome. mRNA-sequencing identified 107 genes 55 significantly (q<0.05) >2-fold increased by seven-day exposure to IFN $\gamma$  (Fig. 1A and 56 Supplementary Table 1).

57 The IFN $\gamma$  receptor genes (*IFNGR1* and *IFNGR2*) were abundantly expressed by urothelium (Supplementary Fig. 1). In all six donors, irrespective of haplotype, IFNy induced gain of human 58 59 leukocyte antigen (HLA) gene expression associated with both major histocompatibility 60 complex (MHC) class I and class II (Supplementary Fig. 2). Gains in expression of  $\beta$ 2-61 microglobulin (B2M), MHC class II invariant chain (CD74) and trans-activator (CIITA), as well 62 as the antigen peptide transporters TAP1 and TAP2, suggest an induced role in modulating antigen-presentation to CD4 T cells (Supplementary Fig. 2). However, urothelial cells are 63 64 unlikely to act as professional antigen presenting cells, because the co-stimulatory B7 family 65 CD80 and CD86 genes were absent and were not inducible by IFN $\gamma$  (Fig. 1C).

Blocking antibodies against the PD-L1 (CD274) immune checkpoint have been trialled clinically
to disinhibit tumour-specific cytotoxic lymphocytes. *CD274* (PD-L1) was strongly induced by
IFNγ (Fig. 1C). By contrast, the inhibitory B7 family member *VSIR* (VISTA) was expressed

constitutively by normal human urothelium but has to-date been overlooked in the bladder
[3]. This indicates that normal urothelium, and likely its malignant counterpart, is a locally
immunosuppressive environment, with induction of PD-L1 by IFNγ acting as a negative
feedback loop to prevent runaway inflammation.

73 IFNy-treatment induced a shift in expression of chemokines and cytokines implicated in 74 immune recruitment, with loss (CCL20, CXCL8, CXCL1, CXCL6, IL23A, IL1B, IL17C, CXCL5 and CXCL2) and gain (CXCL11, CXCL10, CXCL9, IL18BP, IL32) of different signalling factors (Fig. 1B). 75 Of particular note, the CXCL9/10/11-CXCR3 axis is a critical regulator of leukocyte migration, 76 77 differentiation and activation [4], including recruitment of effector T cells. We have shown 78 elsewhere that CXCL10/11 are highly induced following exposure of normal urothelium to BK virus [5] and were the only genes to be further upregulated, rather than repressed, by 79 treatment with exogenous IFNy. We therefore suggest that attenuated BK virus could be used 80 to generate a pro-inflammatory, IFNy-rich local environment akin to that induced by BCG. 81

Cancer subtyping is usually performed by unsupervised clustering of most statistically informative genes detected as transcripts in extracted tumour tissue; the latter representing a heterogeneous mix of tumour, stromal and immune cells. Whilst able to categorise tumours into subsets by similarity, it is a blunt tool for informing therapy. We hypothesised that using signature gene sets representing tissue-specific pathway responses would reduce "noise" and provide greater therapeutic insight.

The *IFNG* transcript can be detected in cancer cohorts but gives weak sensitivity and, as a diffusible factor, IFN $\gamma$  can elicit a response in the tumour even when originating from peritumoural leukocytes. We hypothesised that a urothelial IFN $\gamma$ -response signature would provide a more informative means of detecting IFN $\gamma$ -signalling in a tumour. We therefore

applied a curated urothelial *in vitro* IFNγ-response gene set (Supplementary Table 2) to the
unsupervised clustering of BICa cohorts, yielding an "IFNγ-signature" score.

94 The IFNγ-signature was significantly correlated with *IFNG* transcript in all four BlCa cohorts analysed (see figure legends for details). In NMIBC from the UROMOL2021 cohort [6], the 95 IFNy-signature was weak in Class 2a tumours (Supplementary Fig. 3). In T1 tumours 96 97 (combined from UROMOL2021 [6] and Northwestern Memorial Hospital (NMH) [7] cohorts; Fig. 2A) dichotomised into IFNγ-signature high and low groups, recurrence was 50% more 98 99 likely in patients whose tumours lacked the IFN<sub>γ</sub>-signature (Fig. 2B). A Cox proportional hazards regression analysis of the pseudo-continuous unit-length scaled IFN<sub>γ</sub>-signature 100 scores in T1 tumours predicted a recurrence hazard ratio of 3.174 *p*=0.0230 (Supplementary 101 102 Tables 3-4).

Analysis of TCGA-BLCA data [8] revealed that MIBC lacking the IFN<sub>Y</sub>-signature were most likely 103 to be graded histologically as lymphocyte-negative and of luminal papillary sub-type 104 105 according to the consensus classification [9] (Supplementary Fig. 5). By contrast, MIBC classed 106 as basal/squamous split into two clear subgroups (Fig. 2C). To examine any difference in outcomes associated with the IFN<sub>γ</sub>-signature in basal/squamous tumours, the Lund MIBC 107 108 cohort [10] was analysed in parallel (Supplementary Fig. 6). When dichotomised into IFN $\gamma$ signature high and low groups, overall survival for basal/squamous tumours (pooled from 109 110 TCGA-BLCA and Lund cohorts) was significantly lower in tumours with a weak IFNγ-signature 111 (Fig. 2D). A high survival hazard ratio of 4.846 p=0.0006 was predicted by Cox proportional 112 hazards regression based on the pseudo-continuous IFN<sub>γ</sub>-signature scores from both cohorts (Supplementary Tables 5-7). 113

Bladder cancer is a disease characterised by high mutational loads derived by different 114 processes, whose historic contributions can be assessed using mutational signatures. IFNy-115 signature<sup>high</sup> basal/squamous MIBC tumours had significantly enriched genomic damage from 116 APOBEC enzymes (Supplementary Fig. 7). Widespread APOBEC damage leads to tumour 117 suppressor loss and creates neoantigens which were significantly more abundant in IFN<sub>Y</sub>-118 signature<sup>high</sup> basal/squamous tumours [8]. In an inflammatory context, neoantigens would 119 induce antigen-specific T cell immunity. Conversely, our data suggest that normal and 120 121 malignant urothelium would suppress T cell activation through PD-L1/VISTA checkpoint inhibition, thereby inhibiting type-1 anti-tumour immune responses. It seems most probable 122 that a balance becomes established between activated tumoricidal effector cells and 123 regulatory/immunosuppressive elements. 124

To conclude, this study suggests a reconsideration of the role for IFN<sub>γ</sub> in motivating immune 125 clearance in non-BCG-responsive NMIBC. The IFNγ-signature<sup>high</sup> basal/squamous MIBC 126 127 tumours identified here appear to represent a target for immune checkpoint blockade. However, in the absence of IFN $\gamma$ , expression of PD-L1 is likely to be too low to provide an 128 effective target. We suggest that BCG therapy would be most effective when combined with 129 blocking of both the innate (VISTA [3]) and inducible (PD-L1) immune checkpoints. We 130 anticipate the urothelium-derived transcriptomic IFNy-signature will prove a valuable tool for 131 the design of more efficacious immunotherapy protocols. 132

133

### 134 CRediT Author Statement

135 Conceptualization – SCB, JS

136 Methodology – SCB

- 137 Software ASM, SCB, PE, GS
- 138 Formal analysis SCB, ASM
- 139 Investigation SCB, RGS
- 140 Data Curation ASM, SCB, PE, GS
- 141 Writing SCB, LKT, JS
- 142 Writing Review & Editing SCB, ASM, RGS, PE, GS, LKT, JS
- 143 Visualization SCB
- 144 Supervision SCB, JS
- 145 Project administration SCB
- 146 Funding acquisition JS
- 147

## 148 Acknowledgements

149 This study was funded by York Against Cancer.

150 **Figures** 

151




Fig. 1 – (A) mRNA-sequencing volcano plot for the IFNy-induced normal urothelial 152 153 transcriptome. Data is expressed as transcripts per million (TPM) values and significance was assessed using a likelihood ratio test (LRT) to generate Benjamini-Hochberg corrected g-154 values. The volcano highlights the potential for urothelial-immune signalling via (B) observed 155 shift in chemokine-related gene expression. Stars following gene names indicate >2-fold 156 changes with significance \*=q<0.05, \*\*=q<0.01 and \*\*\*=q<0.001. (C) Urothelial expression 157 of the family of B7 peripheral membrane protein genes. The MHC co-stimulatory molecules 158 159 CD80 and CD86 were not expressed. CD274 ("PD-L1") was significantly induced by IFNy treatment (mean fold change = 5.2; g=0.0095). VSIR ("VISTA") was abundantly expressed 160 and significantly induced by IFN $\gamma$  treatment (mean fold change = 1.2; q=0.0322). For the x-161 axis labels, the B7-family name and other common names are provided in normal font above 162 the italicised HGNC gene name. Data in all panels is derived from normal human urothelium 163

164 *established from six independent donors.* 




Figure 2 – (A) Heatmap and k means clustering based on expression of the IFN $\gamma$ -signature 166 genes in the T1 tumours of UROMOL2021 and Northwestern Memorial Hospital (NMH) 167 cohorts (n=236). The IFN $\gamma$ -signature shows a Spearman rank correlation of 0.66 (p=4x10<sup>-31</sup>) 168 169 with the IFNG gene in T1 tumours. The full UROMOL2021 cohort is shown as Supplemental Fig. 3; [6]). The separate NMH T1 cohort (n=99; [7]) is shown as Supplemental Fig. 4. (B) 170 Kaplan-Meier analysis of IFN<sub>y</sub>-signature high and low T1 tumours with survival data from 171 UROMOL2021 and NMH cohorts combined (n=201). The Kaplan-Meier curve is truncated but 172 no events were recorded after the truncation. A Cox proportional hazards regression was 173 also performed using the unit-length scaled IFN<sub>y</sub>-signature values from T1 tumours which 174

175 predicted a recurrence hazard ratio of 3.174 p=0.0230 (Supplementary Table 4). (C)

- 176 Heatmap for expression of the IFNγ-signature in the Basal/Squamous group of TCGA MIBC
- 177 tumours (n=151; full cohort is shown as Supplemental Fig. 5; [8]; shown classified in red
- according to the consensus report [9]). The IFN<sub>y</sub>-signature shows a Spearman rank
- 179 correlation of 0.87 (p=3.85x10<sup>-47</sup>) with the IFNG gene in Ba/Sq TCGA-BLCA tumours. Similar
- analysis for the Lund MIBC cohort (n=88; [10]) is shown as Supplemental Fig. 6. (D) Kaplan-
- 181 Meier analysis of the IFNγ-signature in Basal/Squamous tumours from TCGA and Lund MIBC
- 182 cohorts combined (n=232). The Kaplan-Meier curve is truncated but no events were recorded
- after the truncation. A Cox proportional hazards regression was also performed using the
- unit-length scaled IFNγ-signature values from both cohorts which predicted a hazard ratio of
- 185 *4.846 p=0.0006 (Supplementary Table 7).*

#### 186 **<u>References</u>**

- 187 [1] Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G. Bacterial immunotherapy for
- 188 cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma
- signaling. Proc Natl Acad Sci U S A. 2020;117:18627-37.
- 190 [2] Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local
- 191 tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol.
- 192 2002;127:20-6.
- 193 [3] Yum JI, Hong YK. Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista,
- 194 baby. Front Oncol. 2021;11:658488.
- 195 [4] Vollmer T, Schlickeiser S, Amini L, et al. The intratumoral CXCR3 chemokine system is predictive
- 196 of chemotherapy response in human bladder cancer. Sci Transl Med. 2021;13.
- [5] Baker SC, Mason AS, Slip RS, et al. BK polyoma virus (BKPyV) is a risk factor for bladder cancer
- 198 through its induction of APOBEC3-mediated genomic damage. bioRxiv.
- 199 2021;<u>https://doi.org/10.1101/2021.05.13.443803</u>.
- 200 [6] Lindskrog SV, Prip F, Lamy P, et al. An integrated multi-omics analysis identifies prognostic
- 201 molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.
- 202 [7] Robertson AG, Groeneveld CS, Jordan B, et al. Identification of Differential Tumor Subtypes of T1
- 203 Bladder Cancer. Eur Urol. 2020;78:533-7.
- [8] Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive Molecular Characterization of Muscle-
- 205 Invasive Bladder Cancer. Cell. 2017;171:540-56 e25.
- 206 [9] Kamoun A, Reynies A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive
- 207 Bladder Cancer. Eur Urol. 2019.
- 208 [10] Sjodahl G, Eriksson P, Liedberg F, Hoglund M. Molecular classification of urothelial carcinoma:
- 209 global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017;242:113-25.
- 210